RT Journal Article SR Electronic T1 ZIKA VIRUS VERTICAL TRANSMISSION IN CHILDREN WITH CONFIRMED ANTENATAL EXPOSURE JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.02.26.20028399 DO 10.1101/2020.02.26.20028399 A1 Patrícia Brasil A1 Zilton Vasconcelos A1 Tara Kerin A1 Claudia Raja Gabaglia A1 Ieda P. Ribeiro A1 Myrna C. Bonaldo A1 Luana Damasceno A1 Marcos V. Pone A1 Sheila Pone A1 Andrea Zin A1 Irena Tsui A1 Kristina Adachi A1 Jose Paulo Pereira, Jr. A1 Stephanie L. Gaw A1 Liege Carvalho A1 Denise C. Cunha A1 Leticia Guida A1 Mirza Rocha A1 James D. Cherry A1 Lulan Wang A1 Saba Aliyari A1 Genhong Cheng A1 Suan-Sin Foo A1 Weiqiang Chen A1 Jae Jung A1 Elizabeth Brickley A1 Maria Elisabeth L. Moreira A1 Karin Nielsen-Saines YR 2020 UL http://medrxiv.org/content/early/2020/03/02/2020.02.26.20028399.abstract AB Background In utero transmission of Zika virus (ZIKV) can lead to adverse infant outcomes, but vertical transmission rates are unknown.Methods Antenatally ZIKV-exposed children were followed prospectively since the time of the Rio de Janeiro epidemic in 2015-16. Serum and urine specimens were collected from infants from birth throughout the first year of life. Specimens were tested by quantitative reverse transcriptase polymerase chain reaction (PCR) and/or IgM antibody capture Zika MAC-ELISA. Infants had neurodevelopmental evaluations, brain imaging, eye examinations, and hearing assessments.Results Over time 130 in utero ZIKV-exposed (mothers PCR+) children were tested with 407 specimens evaluated: 161 sera were tested by PCR and IgM assays, 85 urines by PCR; 84 children (65%) were positive in at least one assay. Among 94 children tested within 3 months of age, 70% were positive (39% serum PCR, 48% urine PCR, 39% IgM). After 3 months, 33% were positive by any laboratory method. Five children were intermittently PCR+ beyond 200 days of life. Concordance between IgM and PCR results was 52%, sensitivity 65%, specificity 40% (with any positive PCR result as the gold standard); IgM and serum PCR were 61% concordant; serum and urine PCR 55%. Most children (65%) were clinically normal. Positive results were seen in 29 of 45 children (64%) with abnormal findings and 55 of 85 normal children (65%), p=0·98. Earlier maternal trimester of infection was associated with positive infant laboratory results but not infant clinical disease (p=0·04).Conclusions ZIKV has a high in utero transmission rate. Laboratory confirmed infection is not necessarily associated with abnormal infant findings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Departamento de Ciência e Tecnologia (DECIT/ 25000.072811/2016-17) do Ministério da Saúde do Brasil (P.B., M.E.M.); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES/ 88887.116627/2016-01; CAPES 88881.130684/2016-01); Brazilian National Council for Scientific and Technological Development CNPq/441098/2016-9; CNPq307282/2017; CNPq440865/2016-6) (P.B., M.E.M., M.C.B); Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ/ E_18/2015TXB (M.E.M.); FAPERJ/239224/E032018 CNE (M.E.M.); FAPERJ/ E_26/202.862/2018 CNE (P.B.); Fondation Christophe and Rodolph Mérieux; ZikAlliance 734548 (P.B.); the Thrasher Research Fund (20164370) (K.N.S., K.A.); the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health AI28697 (K.N.S.), AI1259534-01 (K.N.S., P.B., G.C.), AI140718-01 (K.N.S., P,B.), K08AI141728 (S.L.G), the National Eye Institute (NEI) of the National Institutes of Health AI129847-01 (K.N.S., I.T, P.B.) and the United Kingdom’s Department for International Development (M.E.M.); the Queenan Fellowship from the Foundation for the Society of Maternal-Fetal Medicine (S.L.G) and the ZikaPlan (Preparedness Latin American Network) (M.E.M.); Wellcome Trust & the UK’s Department for International Development (205377/Z/16/Z; https://wellcome.ac.uk/) and the European Union’s Horizon 2020 research and innovation program (https://ec.europa.eu/programmes/horizon2020/) under ZikaPLAN grant agreement No. 734584 (https://zikaplan.tghn.org/) (E.B.)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request